Literature DB >> 9584263

Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test.

P Griffiths1, R Campbell, P Robinson.   

Abstract

The executive dysfunction hypothesis in treated phenylketonuria was investigated by means of the one-back and two-back versions of the continuous performance test. Eleven non-retarded, primary school-age children with classical phenylketonuria who had been treated early and continuously were indistinguishable from healthy, matched controls on the measures and test performance was not predicted by historical or concurrent plasma phenylalanine concentrations. Mean lifetime phenylalanine concentrations for the phenylketonuric subjects were within ranges currently recommended as dietary optima in the United Kingdom. The negative neuropsychological test findings add weight to the rationale for this policy.

Entities:  

Mesh:

Year:  1998        PMID: 9584263     DOI: 10.1023/a:1005339524847

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  27 in total

1.  Phenylketonuria grows up.

Authors: 
Journal:  Lancet       Date:  1991-05-25       Impact factor: 79.321

2.  Neuropsychology of early-treated phenylketonuria: specific executive function deficits.

Authors:  M C Welsh; B F Pennington; S Ozonoff; B Rouse; E R McCabe
Journal:  Child Dev       Date:  1990-12

3.  Error patterns on the continuous performance test in non-medicated and medicated samples of children with and without ADHD: a meta-analytic review.

Authors:  B J Losier; P J McGrath; R M Klein
Journal:  J Child Psychol Psychiatry       Date:  1996-11       Impact factor: 8.982

4.  Intelligence and quality of dietary treatment in phenylketonuria.

Authors:  I Smith; M G Beasley; A E Ades
Journal:  Arch Dis Child       Date:  1990-05       Impact factor: 3.791

5.  Psychosocial aspects in phenylketonuria.

Authors:  J Weglage; B Fünders; K Ullrich; A Rupp; E Schmidt
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

Review 6.  A prefrontal dysfunction model of early-treated phenylketonuria.

Authors:  M C Welsh
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  Correlates of intelligence test results in treated phenylketonuric children.

Authors:  M L Williamson; R Koch; C Azen; C Chang
Journal:  Pediatrics       Date:  1981-08       Impact factor: 7.124

8.  Information processing deficits in children with early and continuously treated phenylketonuria?

Authors:  B A Stemerdink; M W van der Molen; A F Kalverboer; J J van der Meere; M M Hendrikx; J Huisman; L W van der Schot; F M Slijper
Journal:  Acta Paediatr Suppl       Date:  1994-12

Review 9.  Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood.

Authors:  F Güttler
Journal:  Acta Paediatr Scand Suppl       Date:  1980

10.  Neuropsychological deficits in early treated phenylketonuric children.

Authors:  B F Pennington; W J van Doorninck; L L McCabe; E R McCabe
Journal:  Am J Ment Defic       Date:  1985-03
View more
  6 in total

1.  Pupillometric and behavioral markers of a developmental shift in the temporal dynamics of cognitive control.

Authors:  Christopher H Chatham; Michael J Frank; Yuko Munakata
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205

2.  Effects of dietary management of phenylketonuria on long-term cognitive outcome.

Authors:  Shelley Channon; Galya Goodman; Sally Zlotowitz; Caroline Mockler; Philip J Lee
Journal:  Arch Dis Child       Date:  2006-10-26       Impact factor: 3.791

3.  Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review.

Authors:  V L Brumm; C Azen; R A Moats; A M Stern; C Broomand; M D Nelson; R Koch
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

4.  Regression of neuropsychological deficits in early-treated phenylketonurics during adolescence.

Authors:  J Weglage; M Pietsch; J Denecke; A Sprinz; R Feldmann; M Grenzebach; K Ullrich
Journal:  J Inherit Metab Dis       Date:  1999-08       Impact factor: 4.982

5.  Executive dysfunction in treated phenylketonuric patients.

Authors:  Bahare Azadi; Arshia Seddigh; Mehdi Tehrani-Doost; Javad Alaghband-Rad; Mahmoud Reza Ashrafi
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-02-16       Impact factor: 4.785

6.  Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: A meta-analysis of randomized controlled trials.

Authors:  Jinghan Qu; Ting Yang; Ente Wang; Min Li; Chaoyang Chen; Lingyun Ma; Ying Zhou; Yimin Cui
Journal:  Br J Clin Pharmacol       Date:  2019-03-18       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.